Brolucizimab (Beovu®)

Beovu (brolucizumab-dbII) is covered only for FDA‑approved Neovascular (Wet) AMD and specified compendial off‑label neovascular ophthalmic conditions (diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularization, and choroidal neovascular conditions) and is not covered for unlisted uses. Coverage requires intravitreal administration by or under the supervision of an ophthalmologist, adherence to the recommended dosing (6 mg monthly ×3 then 6 mg every 8–12 weeks), and is authorized for a 12‑month approval period.

"Retinopathy of prematurity (listed as an approved off-label compendial use / other neovascular ophthalmic condition)."

Sign up to see full coverage criteria, indications, and limitations.